Genoskin, a leader in ex vivo human skin platforms, has raised Series A funding to accelerate global expansion and strengthen its scientific leadership. The investment will enable Genoskin to scale operations, expand production capacity, and continue developing ethical, human-relevant alternatives to animal testing.
The company is opening new production facilities in Salem, MA (2026) and Toulouse, France (2027), which will double its capacity for human skin models and introduce U.S. production of fresh human primary mast cells for next-day delivery. Increased automation and process optimization will support this scale-up while maintaining the highest standards of quality and reliability.
Genoskin’s human skin platforms provide more predictive insights into drug and medical device safety and efficacy than traditional animal models. Its bio-stabilized, immunocompetent skin samples remain viable for up to seven days, giving biotech, pharma, and cosmetics companies sustainable access to high-quality, human-relevant data.
“Our human-based platforms provide more predictive insights than animal models,” said Pascal Descargues, Ph.D., CEO of Genoskin. “This funding allows us to scale globally and advance our mission to support safer, more effective therapies.”
In addition to expanding infrastructure, Genoskin is enhancing its scientific leadership by developing next-generation biosimulation platforms and immune models. These innovations are designed to accelerate therapeutic development, reduce reliance on animal testing, and support the industry’s shift toward ethical, human-relevant research.
About Genoskin
Genoskin is a biotechnology company transforming drug and vaccine development through its unique expertise in skin biology and immunology. By leveraging donated human skin and proprietary preservation technology, Genoskin provides immunocompetent ex vivo platforms that remain viable for up to seven days post-surgery – enabling more predictive, human-relevant testing than traditional animal or engineered models.
Founded in 2011, Genoskin offers a suite of advanced solutions – including HypoSkin®, ISR Platform®, and InflammaSkin® – to evaluate immune responses, injection site reactions and skin toxicity for a range of therapeutics, biologics, vaccines, medical devices and chemicals. Through a combination of next generation sequencing, advanced imaging and expert scientific guidance, Genoskin helps pharmaceutical, biotech and cosmetics companies accelerate development with greater confidence and accuracy.
Headquartered in both North America and Europe, the company operates state-of-the-art R&D and production facilities in Salem, Massachusetts (USA) and Toulouse, France. It employs 42 staff globally.
Follow Genoskin’s activities: